<?xml version="1.0" ?><ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput xmlns:ns2="local" id="75560"><DrugName>mometasone furoate + azelastine hydrochloride (allergic rhinitis), Hanlim/ Hanmi</DrugName><DrugNamesKey><Name id="42999765">Motesone Plus</Name><Name id="42970295">Nasaflex</Name></DrugNamesKey><DrugSynonyms><Name><Value>mometasone furoate + azelastine hydrochloride (allergic rhinitis), Hanlim</Value></Name><Name><Value>azelastine hydrochloride + mometasone furoate (allergic rhinitis), Hanlim</Value></Name><Name><Value>Nasaflex</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>Motesone Plus</Value><Types><Type>Trade Name</Type></Types></Name><Name><Value>azelastine hydrochloride + mometasone furoate (allergic rhinitis), Hanlim/ Hanmi</Value></Name><Name><Value>mometasone furoate + azelastine hydrochloride (allergic rhinitis), Hanlim/ Hanmi</Value></Name><Name><Value>Moteson Plus</Value></Name><Name><Value>Nazaflex</Value></Name><Name><Value>83919-23-7</Value><Types><Type>CAS RN</Type></Types></Name><Name><Value>58581-89-8</Value><Types><Type>CAS RN</Type></Types></Name></DrugSynonyms><CompanyOriginator id="1004564">Hanlim Pharmaceutical Co Ltd</CompanyOriginator><CompaniesPrimary><Company id="16611">Hanmi Pharmaceutical Co Ltd</Company><Company id="1004564">Hanlim Pharmaceutical Co Ltd</Company></CompaniesPrimary><CrossReferences><SourceEntity id="1004564" type="Company"><TargetEntity id="5000831397" type="organizationId">Hanlim Pharm Co Ltd</TargetEntity></SourceEntity><SourceEntity id="16611" type="Company"><TargetEntity id="5000805170" type="organizationId">Hanmi Pharm Co Ltd</TargetEntity></SourceEntity><SourceEntity id="1107" type="ciIndication"><TargetEntity id="10039085" type="MEDDRA"></TargetEntity><TargetEntity id="-600684678" type="omicsDisease"></TargetEntity><TargetEntity id="298" type="siCondition"></TargetEntity></SourceEntity><SourceEntity id="199" type="Action"><TargetEntity id="196" type="Mechanism">Histamine H1 Receptor Antagonists</TargetEntity></SourceEntity><SourceEntity id="PTGT-00915" type="ciTarget"><TargetEntity id="19255861332693" type="siTarget">Histamine H1 receptor</TargetEntity><TargetEntity id="-722811295" type="omicsTarget"></TargetEntity></SourceEntity></CrossReferences><PhaseHighest id="L">Launched</PhaseHighest><PhaseHighestDetailed><FirstLaunched>Allergic rhinitis - South Korea - Jan-2013</FirstLaunched></PhaseHighestDetailed><IndicationsPrimary><Indication id="1107">Allergic rhinitis</Indication></IndicationsPrimary><ActionsPrimary><Action id="199">Histamine H1 receptor antagonist</Action></ActionsPrimary><ActionsSecondary><Action id="2954">Steroidal anti-inflammatory</Action><Action id="3189">Corticosteroid agonist</Action></ActionsSecondary><Technologies><Technology id="777">Nasal formulation</Technology><Technology id="762">Small molecule therapeutic</Technology><Technology id="603">Systemic formulation unspecified</Technology><Technology id="175">Drug combination</Technology></Technologies><LastModificationDate>2014-10-22T10:41:54.000Z</LastModificationDate><ChangeDateLast>2016-09-27T00:00:00.000Z</ChangeDateLast><AddedDate>2012-01-14T04:29:36.000Z</AddedDate><DevelopmentProfile><Summary><displayLabel>Summary</displayLabel><value>&lt;Summary&gt;&lt;para&gt;&lt;ulink linkType="Company" linkID="1004564"&gt;Hanlim Pharmaceutical&lt;/ulink&gt; has developed and launched Nasaflex, a  combination of the corticosteroid &lt;ulink linkType="Drug" linkID="13594"&gt;mometasone furoate&lt;/ulink&gt; and the histamine H1 receptor antagonist &lt;ulink linkType="Drug" linkID="16957"&gt;azelastine hydrochloride&lt;/ulink&gt;, for the   potential treatment of allergic rhinitis, as a nasal spray [&lt;ulink linkType="Reference" linkID="1254421"&gt;1254421&lt;/ulink&gt;]. In January 2013, Hanlim launched  the combination   [&lt;ulink linkType="Reference" linkID="1463425"&gt;1463425&lt;/ulink&gt;]. Collaborator &lt;ulink linkType="Company" linkID="16611"&gt;Hanmi&lt;/ulink&gt; has also launched the combination (as Motesone Plus) by September 2013  [&lt;ulink linkType="Reference" linkID="1358119"&gt;1358119&lt;/ulink&gt;], [&lt;ulink linkType="Reference" linkID="1497562"&gt;1497562&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Summary&gt;</value></Summary><Regulatory><displayLabel>Regulatory</displayLabel><value>&lt;Regulatory&gt;&lt;para&gt;In December 2011, launch was planned for September 2012 [&lt;ulink linkType="Reference" linkID="1254421"&gt;1254421&lt;/ulink&gt;]. By January 2013, the Korean FDA approved the combination, with a six-year postmarketing surveillance (PMS) period. At that time, launch was expected by mid-year  following price negotiations  [&lt;ulink linkType="Reference" linkID="1358119"&gt;1358119&lt;/ulink&gt;]. &lt;/para&gt;&lt;/Regulatory&gt;</value></Regulatory><Premarketing><displayLabel>Premarketing</displayLabel><value>&lt;Premarketing&gt;&lt;para&gt;In April 2011, a multicenter, randomized, double-blind, phase III trial (&lt;ulink linkType="Protocol" linkID="82370"&gt;NCT01470053&lt;/ulink&gt;; HL_NSFX_301) began in    patients with perennial allergic rhinitis (n = 324). The trial was expected to complete in February 2012 [&lt;ulink linkType="Reference" linkID="1254421"&gt;1254421&lt;/ulink&gt;].&lt;/para&gt;&lt;/Premarketing&gt;</value></Premarketing></DevelopmentProfile><IDdbDevelopmentStatus><DevelopmentStatusCurrent><Company id="1004564">Hanlim Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1107">Allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-31T00:00:00.000Z</StatusDate><Source id="1463425" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusCurrent><Company id="16611">Hanmi Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="L" sortOrder="15">Launched</DevelopmentStatus><Indication id="1107">Allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-09-01T00:00:00.000Z</StatusDate><Source id="1497562" type="SERIAL"></Source></DevelopmentStatusCurrent><DevelopmentStatusHistoric><Company id="1004564">Hanlim Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="C3" sortOrder="12">Phase 3 Clinical</DevelopmentStatus><Indication id="1107">Allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2011-04-30T00:00:00.000Z</StatusDate><Source id="1254421" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="1004564">Hanlim Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1107">Allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1358119" type="SERIAL"></Source></DevelopmentStatusHistoric><DevelopmentStatusHistoric><Company id="16611">Hanmi Pharmaceutical Co Ltd</Company><Country id="KR">South Korea</Country><DevelopmentStatus id="R" sortOrder="14">Registered</DevelopmentStatus><Indication id="1107">Allergic rhinitis</Indication><StatusDate xmlns:ns3="http://serviceversion" xmlns:ns2="http://v2.drugs.soap.contract.service.ls.thomsonreuters.com/">2013-01-01T00:00:00.000Z</StatusDate><Source id="1358119" type="SERIAL"></Source></DevelopmentStatusHistoric></IDdbDevelopmentStatus><Targets><Target id="PTGT-00915"><Name>Histamine H1 receptor</Name><SwissprotNumbers><Swissprot>P30546</Swissprot><Swissprot>P31389</Swissprot><Swissprot>P31390</Swissprot><Swissprot>P35367</Swissprot><Swissprot>P70174</Swissprot><Swissprot>Q9N2B0</Swissprot><Swissprot>Q9N2B1</Swissprot><Swissprot>Q9N2B2</Swissprot></SwissprotNumbers></Target></Targets><ReasonsForUpdate><ReasonForUpdate><Reason>Editorial Amendments</Reason><Description>Minor editorial amendment</Description></ReasonForUpdate></ReasonsForUpdate><CountsByCompanies><Company><Company id="1004564">Hanlim Pharmaceutical Co Ltd</Company><CountAsPrincipalActive>0</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>0</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company><Company><Company id="1060189">Hanmi Holdings Co Ltd</Company><CountAsPrincipalActive>1</CountAsPrincipalActive><CountAsPrincipalInactive>0</CountAsPrincipalInactive><CountAsPartnerActive>1</CountAsPartnerActive><CountAsPartnerInactive>0</CountAsPartnerInactive><CountTotal>1</CountTotal></Company></CountsByCompanies><CountsByTypes><Type><Type sortOrder="4">Drug - Development/Commercialization License</Type><CountActive>1</CountActive><CountInactive>0</CountInactive><CountTotal>1</CountTotal></Type></CountsByTypes><StructureSmiles><Smiles>C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)OC(=O)c5ccco5)C)O)Cl)C</Smiles><Smiles>C[C@@H]1C[C@H]2[C@@H]3CCC4=CC(=O)C=C[C@@]4([C@]3([C@H](C[C@@]2([C@]1(C(=O)CCl)OC(=O)c5ccco5)C)O)Cl)C.CN1CCCC(CC1)n2c(=O)c3ccccc3c(n2)Cc4ccc(cc4)Cl.Cl</Smiles><Smiles>CN1CCCC(CC1)n2c(=O)c3ccccc3c(n2)Cc4ccc(cc4)Cl</Smiles></StructureSmiles><Deals><Deal id="143538" title="Hanmi and Hanlim to jointly develop combination of mometasone furoate and azelastine hydrochloride as nasal spray"></Deal></Deals><PatentFamilies><PatentFamily id="1706795" number="WO-2012074231" title="Pharmaceutical composition including mometasone furoate and azelastine hydrochloride for nasal administration"></PatentFamily><PatentFamily id="2756127" number="WO-2014092346" title="Bitter taste masked pharmaceutical formulation comprising corticosteroid, antihistamine and stevia"></PatentFamily></PatentFamilies><PatentFamilyCountsByTypes><PatentFamilyCountsByType><Type sortorder="12">Product</Type><Count>1</Count></PatentFamilyCountsByType><PatentFamilyCountsByType><Type sortorder="5">Formulation</Type><Count>1</Count></PatentFamilyCountsByType></PatentFamilyCountsByTypes><PatentFamilyCountsByCompanies><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hanlim Pharmaceutical Co Ltd" id="1004564"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany><PatentFamilyCountsByCompany><CompanyLink nameDisplay="Hanmi Holdings Co Ltd" id="1060189"></CompanyLink><CountAsOwner>1</CountAsOwner><CountAsThirdParty>0</CountAsThirdParty><CountTotal>1</CountTotal></PatentFamilyCountsByCompany></PatentFamilyCountsByCompanies><hasSWOTs>N</hasSWOTs></ns2:com.thomsonreuters.ls.service.contract.soap.drugs.v2.DrugRecordOutput>